[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 15 sources · 3 days · First seen · Last updated

EMA recommendation for Eli Lilly obesity medication

Overview

The European Medicines Agency (EMA) has issued a positive recommendation via its Committee for Medicinal Products for Human Use (CHMP) for Eli Lilly’s oral medication, Foundayo (orforglipron). The drug is a small-molecule GLP-1 receptor agonist designed to treat obesity and type 2 diabetes in adults.

Clinical studies involving approximately 4,740 to 4,840 participants demonstrated weight loss ranging from 5% to 11% depending on dosage. Reported side effects include gastrointestinal issues such as nausea, vomiting, and diarrhea. The medication is noted for its ease of administration as a once-daily tablet.

The recommendation now moves to the European Commission for a final decision, which is expected within approximately two months. Once authorized, individual EU member states will be responsible for negotiating pricing and reimbursement protocols.

Entities

European Medicines Agency · Eli Lilly · European Commission · Novo Nordisk · orforglipron

Timeline

  1. [HEALTH] 6 sources
    Eli Lilly's Foundayo receives positive EMA recommendation for obesity and diabetes

    The EMA has recommended the approval of Eli Lilly’s oral medication Foundayo for treating obesity and type 2 diabetes in adults, marking a significant step toward its European market launch.

  2. [BUSINESS] 9 sources
    Eli Lilly obesity pill receives EMA recommendation for approval

    The EMA has recommended approval for Eli Lilly’s oral obesity and type 2 diabetes pill, orforglipron, paving the way for its potential release across the European Union.

Sources

accioncr.com · ariadna.elmundo.es · arynews.tv · fehmarn24.de · forbes.com.br · in.gr · isanidad.com · kreiszeitung.de · leinetal24.de · merca2.es · mononews.gr · noticiasdemalaga.es · nutridieta.com · op-online.de · valor.globo.com